Hepatic steatosis and HIV infection

Maria Ristig, Henning Drechsler, William G. Powderly

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

There is increasing concern that patients with chronic HIV infection may be at increased risk of nonalcoholic fatty liver disease (NAFLD), which can evolve into nonalcoholic steatohepatitis (NASH) and cirrhosis. Multiple factors have been hypothesized to be necessary for the development and progression of this condition. Potential risk factors, which tend to accumulate in the HIV-positive population, include metabolic derangements, chronic inflammation, hepatitis coinfection, and treatment with certain nucleoside reverse transcriptase inhibitors (NRTIs). HIV-associated conditions such as hyperlactatemia and lipodystrophy frequently overlap with fatty liver disease. The cornerstone of management of HIV-associated fatty liver disease is currently to treat the predominant underlying condition. There is a need for more epidemiologic data to better define the role of comorbidities and drugs in the development of NAFLD. Further work is also needed to elucidate the pathogenesis and to evaluate the therapeutic effect of treating comorbidities and avoiding certain antiretroviral drugs.

Original languageEnglish (US)
Pages (from-to)356-365
Number of pages10
JournalAIDS Patient Care and STDs
Volume19
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

HIV Infections
HIV
Fatty Liver
Comorbidity
Liver Diseases
Liver
Lipodystrophy
Reverse Transcriptase Inhibitors
Therapeutic Uses
Chronic Hepatitis
Coinfection
Nucleosides
Pharmaceutical Preparations
Fibrosis
Inflammation
Population
Non-alcoholic Fatty Liver Disease
Therapeutics
Hyperlactatemia

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Hepatic steatosis and HIV infection. / Ristig, Maria; Drechsler, Henning; Powderly, William G.

In: AIDS Patient Care and STDs, Vol. 19, No. 6, 06.2005, p. 356-365.

Research output: Contribution to journalArticle

Ristig, Maria ; Drechsler, Henning ; Powderly, William G. / Hepatic steatosis and HIV infection. In: AIDS Patient Care and STDs. 2005 ; Vol. 19, No. 6. pp. 356-365.
@article{9a99cc7e873540aba82abae46712a6fc,
title = "Hepatic steatosis and HIV infection",
abstract = "There is increasing concern that patients with chronic HIV infection may be at increased risk of nonalcoholic fatty liver disease (NAFLD), which can evolve into nonalcoholic steatohepatitis (NASH) and cirrhosis. Multiple factors have been hypothesized to be necessary for the development and progression of this condition. Potential risk factors, which tend to accumulate in the HIV-positive population, include metabolic derangements, chronic inflammation, hepatitis coinfection, and treatment with certain nucleoside reverse transcriptase inhibitors (NRTIs). HIV-associated conditions such as hyperlactatemia and lipodystrophy frequently overlap with fatty liver disease. The cornerstone of management of HIV-associated fatty liver disease is currently to treat the predominant underlying condition. There is a need for more epidemiologic data to better define the role of comorbidities and drugs in the development of NAFLD. Further work is also needed to elucidate the pathogenesis and to evaluate the therapeutic effect of treating comorbidities and avoiding certain antiretroviral drugs.",
author = "Maria Ristig and Henning Drechsler and Powderly, {William G.}",
year = "2005",
month = "6",
doi = "10.1089/apc.2005.19.356",
language = "English (US)",
volume = "19",
pages = "356--365",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Hepatic steatosis and HIV infection

AU - Ristig, Maria

AU - Drechsler, Henning

AU - Powderly, William G.

PY - 2005/6

Y1 - 2005/6

N2 - There is increasing concern that patients with chronic HIV infection may be at increased risk of nonalcoholic fatty liver disease (NAFLD), which can evolve into nonalcoholic steatohepatitis (NASH) and cirrhosis. Multiple factors have been hypothesized to be necessary for the development and progression of this condition. Potential risk factors, which tend to accumulate in the HIV-positive population, include metabolic derangements, chronic inflammation, hepatitis coinfection, and treatment with certain nucleoside reverse transcriptase inhibitors (NRTIs). HIV-associated conditions such as hyperlactatemia and lipodystrophy frequently overlap with fatty liver disease. The cornerstone of management of HIV-associated fatty liver disease is currently to treat the predominant underlying condition. There is a need for more epidemiologic data to better define the role of comorbidities and drugs in the development of NAFLD. Further work is also needed to elucidate the pathogenesis and to evaluate the therapeutic effect of treating comorbidities and avoiding certain antiretroviral drugs.

AB - There is increasing concern that patients with chronic HIV infection may be at increased risk of nonalcoholic fatty liver disease (NAFLD), which can evolve into nonalcoholic steatohepatitis (NASH) and cirrhosis. Multiple factors have been hypothesized to be necessary for the development and progression of this condition. Potential risk factors, which tend to accumulate in the HIV-positive population, include metabolic derangements, chronic inflammation, hepatitis coinfection, and treatment with certain nucleoside reverse transcriptase inhibitors (NRTIs). HIV-associated conditions such as hyperlactatemia and lipodystrophy frequently overlap with fatty liver disease. The cornerstone of management of HIV-associated fatty liver disease is currently to treat the predominant underlying condition. There is a need for more epidemiologic data to better define the role of comorbidities and drugs in the development of NAFLD. Further work is also needed to elucidate the pathogenesis and to evaluate the therapeutic effect of treating comorbidities and avoiding certain antiretroviral drugs.

UR - http://www.scopus.com/inward/record.url?scp=21844476158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844476158&partnerID=8YFLogxK

U2 - 10.1089/apc.2005.19.356

DO - 10.1089/apc.2005.19.356

M3 - Article

VL - 19

SP - 356

EP - 365

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 6

ER -